← Back to headlines
Arrowhead Pharma Anticipates SHASTA-3/4 Topline Results in Q3
Arrowhead Pharmaceuticals expects to release topline data for its SHASTA-3/4 trials in the third quarter and plans to submit an sNDA for SHTG before the end of 2026.
8 May, 03:12 — 8 May, 03:12
Sources
Showing 1 of 1 sources
